Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
Bone ; 167: 116638, 2023 02.
Article in English | MEDLINE | ID: mdl-36464243

ABSTRACT

Anterior cruciate ligament (ACL) tear leads to post-traumatic osteoarthritis (PTOA), a significant clinical burden worldwide that currently has no cure. Recent studies suggest a role of subchondral bone adaptations in the development of PTOA. Particularly, microstructural changes in the rod-and-plate microstructure of subchondral bone may precede and contribute to OA progression. In this study, we quantified microstructural changes in subchondral trabecular rods and plates after ACL-transection for the first time in the well-established preclinical canine model of PTOA and investigated the therapeutic potentials of a bisphosphonate (zoledronate) and NSAID treatment (meloxicam). Unilateral hindlimb ACL transection was performed on skeletally-mature (2-year-old, N = 20) and juvenile (10-month-old, N = 20) male beagles. Animals were assigned to 4 groups (N = 5): ACLT, un-operated control, ACLT with zoledronate, and ACLT with meloxicam treatment. Subchondral bone microstructure was evaluated by micro-computed tomography and cartilage integrity was evaluated histologically. We found that ACL-induced subchondral bone changes depended on skeletal maturity of animals. In mature animals, significant loss of trabecular plates that resulted in reduced PR ratio occurred at Month 1 and persisted until Month 8. Zoledronate treatment prevented trabecular plate loss while meloxicam treatment did not. Whether cartilage degeneration is also attenuated warrants further investigation. In juvenile animals that have not reached skeletal maturity, transient changes in trabecular plate and rod microstructure occurred at Month 3 but not Month 9. Neither zoledronate nor meloxicam treatment attenuated bone microstructural changes or cartilage damages. Findings from this study suggest that early inhibition of bone resorption by bisphosphonate after injury may be a promising therapeutic approach to prevent alterations in subchondral bone microstructure associated with PTOA. Our results further demonstrate that pathogenesis of PTOA may differ between adolescent and adult patients and therefore require distinct management strategies.


Subject(s)
Anterior Cruciate Ligament Injuries , Cartilage, Articular , Osteoarthritis , Animals , Male , Dogs , Zoledronic Acid/pharmacology , Zoledronic Acid/therapeutic use , X-Ray Microtomography , Meloxicam/pharmacology , Meloxicam/therapeutic use , Bone and Bones/pathology , Osteoarthritis/pathology , Anterior Cruciate Ligament Injuries/drug therapy , Anterior Cruciate Ligament Injuries/complications , Cartilage, Articular/pathology , Disease Models, Animal
2.
J Orthop Res ; 32(3): 477-84, 2014 Mar.
Article in English | MEDLINE | ID: mdl-24243710

ABSTRACT

PURPOSE: To evaluate the effect of intervention timing of Sr treatment on trabecular bone microstructure and mechanics. METHODS: Ninety female rats were randomly divided into three batches with three groups in each batch. Each group was divided according to the initiation timing of vehicle or strontium compound (SrC), which was at week 0 (early), 4 (mid-term) and 8 (late) after the ovariectomy, respectively. The treatment lasted for 12 weeks. The trabecular bone biomechanical properties, trabecular bone tissue mechanical properties, trabecular bone microstructure, and bone remodeling were analyzed with mechanical testing, nanoindentation, microCT, and histomorphometry, respectively. The osteoblast and osteoclast phenotypic genes were analyzed with real-time polymerase chain reaction (PCR). RESULTS: Early and mid-term Sr treatment significantly increased biomechanical properties of trabecular bone, which was associated with increased microarchitecture parameters, increased bone formation parameters and up-regulation of osteoblast-related gene expression. Late Sr treatment failed to exert a beneficial effect on any of those parameters. CONCLUSIONS: The beneficial effect of Sr was dependent on the intervention timing in ovariectomized rats.


Subject(s)
Bone and Bones/drug effects , Osteoporosis, Postmenopausal/drug therapy , Strontium/administration & dosage , Animals , Bone Resorption/prevention & control , Compressive Strength/drug effects , Female , Humans , Osteoblasts/drug effects , Osteoblasts/metabolism , Osteogenesis/drug effects , Ovariectomy , Random Allocation , Rats , Rats, Sprague-Dawley , Strontium/blood
3.
Bone ; 49(6): 1290-8, 2011 Dec.
Article in English | MEDLINE | ID: mdl-21925296

ABSTRACT

BACKGROUND: The mechanism for the uncoupling effects of Sr on bone remains to be evaluated. Osteoblasts play important roles in osteoclastogenesis through regulating receptor activated nuclear factor kappa B (RANK) ligand (RANKL) and osteoprotegerin (OPG) expression. We hypothesize that OPG plays an important role in the cross-talk between osteoclasts and osteoblasts in response to Sr treatment. MATERIALS AND METHODS: MC3T3E1 cells were treated with Sr chloride (0-3 mM) and conditioned media were collected at 24h after the treatment. The effect of conditioned media on osteoclastogenesis was evaluated by tartrate-resistant acid phosphatase (TRAP) staining and bone resorption pits analysis. OPG and RANKL mRNA expressions in osteoblastic cells and protein secretion in the conditioned media were analyzed with real-time PCR and ELISA assay, respectively. The role of OPG in Sr-mediated inhibition of osteoclastogenesis was further evaluated with anti-OPG antibody in pre-osteoclastic cells. The role of OPG in Sr-mediated uncoupling effects on osteoporotic bone was evaluated by an animal study. Ovariectomized rats were oral administrated with vehicle or Sr chloride for two months supplemented with anti-IgG antibody (control) or anti-OPG antibody. The effects of OPG neutralization after Sr treatment on bone metabolism were analyzed by microCT, bone histomorphometry and biochemical analysis. RESULTS: The conditioned media derived from Sr-treated osteoblastic cells exerted a dose-dependent inhibitory effect on osteoclastic differentiation and resorptive activity in pre-osteoclastic cells. OPG mRNA expression and protein secretion in osteoblastic cells were significantly increased after Sr treatment. Neutralization with anti-OPG antibody abolished the inhibitory effect of conditioned media on RANKL-induced osteoclastogenesis. The uncoupling effects of Sr treatment on trabecular bone were evidenced by greater bone volume and trabecular number, greater osteoid surface and bone formation rate, while less osteoclast surface. These effects were attenuated by the OPG neutralization by anti-OPG antibody injection. CONCLUSION: The evidences from the in vitro and in vivo studies suggested that OPG played an important role in the uncoupling effect of Sr on bone metabolism, possibly by acting as a cross-talk molecule between osteoclasts and osteoblasts in response to Sr treatment.


Subject(s)
Osteoblasts/metabolism , Osteoblasts/pathology , Osteoclasts/metabolism , Osteoclasts/pathology , Osteoprotegerin/metabolism , Strontium/pharmacology , Anabolic Agents/pharmacology , Animals , Antibodies, Neutralizing/pharmacology , Bone Resorption/drug therapy , Bone Resorption/genetics , Bone Resorption/pathology , Cell Differentiation/drug effects , Cell Line , Culture Media, Conditioned/pharmacology , Female , Gene Expression Regulation/drug effects , Mice , Osteoblasts/drug effects , Osteoclasts/drug effects , Osteogenesis/drug effects , Osteoprotegerin/genetics , Ovariectomy , RANK Ligand/genetics , RANK Ligand/metabolism , RANK Ligand/pharmacology , RNA, Messenger/genetics , RNA, Messenger/metabolism , Rats , Rats, Sprague-Dawley , Strontium/therapeutic use , Tibia/drug effects , Tibia/pathology
4.
J Bone Miner Res ; 26(6): 1272-82, 2011 Jun.
Article in English | MEDLINE | ID: mdl-21611968

ABSTRACT

Strontium (Sr) exerts an anabolic and antiresorptive effect on bone, but the mechanism remains unknown. Osteoprotegerin (OPG) expressed by osteoblasts plays an important role in regulating bone homeostasis by inhibiting osteoclastogenesis and bone resorption. This study aims at evaluating the role of OPG in Sr-mediated inhibition of osteoclastogenesis and bone resorption. Six-week-old Opg knockout (KO) male mice and their wild-type (WT) littermates were treated orally with vehicle (Veh) or Sr compound (4 mmol/kg) daily for 8 weeks. Bone mass and microstructure in the lumbar spine (L(4)) and proximal tibia were analyzed with micro-computed tomography (µCT). Bone remodeling was evaluated with serum biochemical analysis and static and dynamic bone histomorphometry. Osteoclast differentiation potential and gene expression were analyzed in bone marrow cells. The findings demonstrate that Sr compound treatment results in greater bone volume and trabecular number than Veh treatment in WT mice. The anabolic response of trabecular bone to Sr treatment is attenuated in KO mice. Although Sr treatment significantly decreases in vitro osteoclastogenesis and bone resorption in WT mice, these effects are attenuated in KO mice. Furthermore, Sr treatment profoundly increases Opg gene expression in the tibias and OPG protein levels in the sera of WT mice. This study concludes that the inhibition of osteoclastogenesis and bone resorption is possibly associated with OPG upregulation by Sr treatment.


Subject(s)
Bone Resorption/drug therapy , Bone Resorption/pathology , Osteoclasts/pathology , Osteogenesis , Osteoprotegerin/deficiency , Strontium/therapeutic use , Animals , Biomarkers/blood , Bone Marrow/drug effects , Bone Marrow/metabolism , Bone Marrow/pathology , Bone Remodeling/drug effects , Bone Resorption/blood , Bone Resorption/physiopathology , Cell Differentiation/drug effects , Cell Differentiation/genetics , Dose-Response Relationship, Drug , Gene Expression Regulation/drug effects , Lumbar Vertebrae/diagnostic imaging , Lumbar Vertebrae/drug effects , Lumbar Vertebrae/pathology , Male , Mice , Mice, Inbred C57BL , Mice, Knockout , Osteoblasts/drug effects , Osteoblasts/metabolism , Osteoblasts/pathology , Osteoclasts/drug effects , Osteoclasts/metabolism , Osteogenesis/drug effects , Osteoprotegerin/genetics , Osteoprotegerin/metabolism , RANK Ligand/genetics , RANK Ligand/metabolism , Radiography , Strontium/pharmacology , Tibia/diagnostic imaging , Tibia/drug effects , Tibia/pathology
5.
Langmuir ; 25(15): 8419-22, 2009 Aug 04.
Article in English | MEDLINE | ID: mdl-20050040

ABSTRACT

A supramolecular hydrogel based on D-amino acids, which resists hydrolysis catalyzed by proteinase K and offers long-term biostability, exhibits controlled release in vivo, as proved by the pharmacokinetics of encapsulated 125I tracers and the SPECT imaging of the hydrogel-encapsulated 131I tracers. As the first in vivo imaging investigation of the drug release properties of the supramolecular hydrogel, isotope encapsulation serves as a valid, useful assay for characterizing the controlled release properties of supramolecular hydrogels in vivo. Our results indicate that supramolecular hydrogels promise new biomaterials for controlled drug release.


Subject(s)
Amino Acids/chemistry , Dipeptides/chemistry , Drug Delivery Systems , Hydrogel, Polyethylene Glycol Dimethacrylate/chemistry , Biocompatible Materials/chemistry , Drug Carriers , Humans , Hydrogels/chemistry , Iodine Radioisotopes/chemistry , Materials Testing , Microscopy, Electron, Transmission/methods , Models, Chemical , Sodium Iodide/chemistry , Time Factors , Tomography, Emission-Computed, Single-Photon/methods
SELECTION OF CITATIONS
SEARCH DETAIL
...